Conju-probe, San Diego, California, USA.
Bharath University, Chennai, Tamil Nadu, 600126, India.
Curr Med Chem. 2023;30(12):1458-1461. doi: 10.2174/0929867329666220922095343.
COVID-19 is a contagious disease. Paxlovid, a combination of Nirmatrelvir and Ritonavir, was granted emergency use authorization by the United States Food and Drug Administration (FDA) for the treatment of COVID-19 on December 22, 2021. These are peptidomimetic coronavirus main protease inhibitors. Nirmatrelvir is a proline derivative. The present patent describes similar proline- like compounds, their preparation, use, pharmaceutical composition, and treatment.
COVID-19 是一种传染性疾病。奈玛特韦/利托那韦片（Paxlovid）于 2021 年 12 月 22 日获得美国食品药品监督管理局（FDA）的紧急使用授权，用于治疗 COVID-19，它是由奈玛特韦（nirmatrelvir）和利托那韦（ritonavir）组成的复方制剂。这两种都是拟肽类的冠状病毒主蛋白酶抑制剂。奈玛特韦是脯氨酸衍生物。本专利描述了类似的脯氨酸样化合物、其制备、用途、药物组合物和治疗方法。
